NCT01021787

Brief Summary

To determine the penetration of micronized and pigmentary TiO2 in Formulas 283419 2 and 760.001 into the stratum corneum of Compromised (Induced Sunburn) human skin via skin stripping of human subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Dec 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2009

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 30, 2009

Completed
1 day until next milestone

Study Start

First participant enrolled

December 1, 2009

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

June 14, 2011

Status Verified

November 1, 2009

Enrollment Period

Same day

First QC Date

November 25, 2009

Last Update Submit

June 13, 2011

Conditions

Keywords

Sun Protection

Outcome Measures

Primary Outcomes (1)

  • Determine degree of penetration of TiO2 down to 16 -20 tape strips of human skin

    Single application

Interventions

Topical cream

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All subjects must:
  • be between the ages of 18 and 65.
  • agree to not participate in any other product evaluations or clinical evaluations during the course of this study.
  • have read, understood and signed an Informed Consent Form.
  • have intact skin in the treatment area.
  • have fair skin - Skin Types I, or II - as defined in Appendix II.
  • be able to understand and willing to follow all study procedures and restrictions.

You may not qualify if:

  • Subjects will be excluded from participating in the study if they:
  • are female and are pregnant or lactating \[must be using an acceptable method of birth control if of child bearing potential\].\*
  • exhibit any visible symptoms of skin disease, such as psoriasis or eczema, or skin abnormality (including active dermal lesions, uneven skin tone or scars) which might interfere with interpretation of the study results. The presence of nevi, blemishes, or moles will be acceptable if, in the Investigator's judgement, they will not interfere with the study results or skin stripping procedures.
  • have a history of allergic responses to sunscreens or other products similar to those included in this study.
  • have very dry or scaly skin on the test site.
  • have diabetes.
  • have a history of abnormal responses to sunlight, such as a phototoxic or photoallergic response.
  • have an existing sunburn or suntan, or been to a tanning booth which would interfere with interpretation of the study results.
  • have used self tanners within the past two weeks.
  • have excessive hair at the test site area which could, in the opinion of the investigator, interfere with the interpretation of the results.
  • have participated in a research drug trial or patch test within six weeks of beginning this study.
  • have a known sensitivity to Scotch 600 Transparent Tape.
  • are currently receiving, or within the past two weeks received, topical or systemic medication which could, in the opinion of the investigator, interfere with the interpretation of the results, affect the safety of the subject, or which may change the body's response to ultraviolet light.
  • are currently taking any of the drugs listed on the next page. In addition, the use of St. John's Wort or other similar dietary supplements, aspirin or OTC ibuprofen is contraindicated for the duration of the study. Low dose daily aspirin use, 81 mgs, taken for heart attack prevention is excluded.
  • Acceptable methods of birth control that can be used during the course of the study are: oral contraceptive pill, intrauterine device, patch, injection, condom with spermicide, partner vasectomy, bilateral tubal ligation, abstinence or evidence of non childbearing potential (i.e., post-menopausal \[one year without menstrual period\], hysterectomy or bilateral ovariectomy).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hill Top Research

Winnipeg, Manitoba, R3L2W2, Canada

Location

MeSH Terms

Conditions

Sunburn

Interventions

titanium dioxide

Condition Hierarchy (Ancestors)

Photosensitivity DisordersSkin DiseasesSkin and Connective Tissue DiseasesBurnsWounds and Injuries

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 25, 2009

First Posted

November 30, 2009

Study Start

December 1, 2009

Primary Completion

December 1, 2009

Study Completion

December 1, 2009

Last Updated

June 14, 2011

Record last verified: 2009-11

Locations